Ex-Goldman Sachs and Morgan Stanley Executives Join iRegene Therapeutics. The Company Secures RMB 470 Million in Two Months. Is iRegene Therapeutics Entering IPO Countdown?

China's domestically originated induced pluripotent stem cell (iPSC) sector has achieved a new breakthrough.

On July 2, iRegene Therapeutics Co., Ltd. announced the completion of its RMB 260 million Series C+ financing round. This round was led by Chengdu Sci-Tech Innovation Investment. Co-investors include China Capital Management, Wuxi Capital Group, Dingtai Star, Nanjing Xinjiye and HONY CAPITAL. Existing shareholders Yuanxi Haihe Biomedical Industry Fund and Jinshajiang United Runpu Yuanfeng Venture Capital made follow-on investments.

In just two months from June to July this year, iRegene Therapeutics completed two consecutive financing rounds: Series C1 worth RMB 210 million and Series C+ worth RMB 260 million, bringing the total amount of funds raised to RMB 470 million. Local sci-tech innovation platforms, brokerage-backed capitals, pharmaceutical enterprises and specialized medical funds have all participated in the investment, while existing shareholders continued to increase their holdings.

Behind the collective bet from investors lies a fundamental shift in the investment logic governing the iPSC industry. Pure technological narratives no longer hold appeal; enterprises boasting scalable platforms, reliable clinical translation prospects and clear capitalization routes have become the prime targets of capital inflows. iRegene Therapeutics’two consecutive large-scale financing rounds stand as a typical example reflecting this new industry trend.

The evaluation criteria for iPSC companies in the current capital market have undergone a shift. Single-product enterprises are gradually falling out of favor, while platform biotechs with reusable core technologies and the capability to advance multiple clinical pipelines in parallel can consistently attract capital support. iRegene Therapeutics’core competitive moat lies in its self-developed AI-aided chemical induction underlying technology platform with global intellectual property rights, which also serves as its core differentiator from most product-focused cell therapy companies.

This technology leverages AI algorithms to optimize small molecule combinations, enabling directed cell induction and simultaneous functional modification. It also establishes a standardized chemical preparation system, fundamentally resolving the industry pain points of traditional cell therapies, such as large batch-to-batch variation, high production costs, and difficulties in large-scale off-the-shelf manufacturing. More importantly, the platform boasts robust cross-indication scalability. The core underlying technology can continuously incubate multiple clinical pipelines targeting aging-related diseases to form a diversified multi-product portfolio.

Drawing on its platform capabilities, iRegene Therapeutics has built a comprehensive product portfolio covering two high-demand therapeutic areas: central nervous system degenerative diseases and rare ophthalmic diseases. NouvNeu001 targets Parkinson’s disease, serving as the company’s flagship asset with the most advanced clinical progress and the highest market attention. NouvNeu004, developed for multiple system atrophy parkinsonian type (MSA-P), has successfully entered clinical trials. It is also the world’s first off-the-shelf iPSC-derived cell therapy product for multiple system atrophy (MSA) to advance into clinical development. The ophthalmic NouvSight pipeline focuses on irreversible visual impairment and retinitis pigmentosa, expected to create the company’s second growth engine.

The parallel clinical advancement of multiple pipelines fully validates the replicability of iRegene Therapeutics’ AI-aided chemical induction platform technology. It also enables the company to build a multi-layered clinical asset portfolio, thereby diversifying the R&D risks associated with a single project.

Beyond its robust pipeline layout, the company’s efficient global clinical execution capability further consolidates its long-term value. Its core asset NouvNeu001 is conducting Phase II clinical trials simultaneously in China and the United States. The first patient dosing has been completed at Weill Cornell Medicine in the US, while five top-tier clinical centers across China have rapidly initiated patient enrollment. This product has also obtained dual designations: the U.S. FDA Fast Track Designation (FTD) and Regenerative Medicine Advanced Therapy (RMAT). NouvNeu001 stands as the world’s first cell therapy product in the iPSC space to secure both designations concurrently. iRegene Therapeutics demonstrates strong execution capacity in conducting cross-border parallel clinical trials and efficiently engaging with global regulatory authorities.

From a market size perspective, all pipelines of iRegene Therapeutics target aging-related disease segments driven by global population aging. Parkinson’s disease, multiple system atrophy and retinal degenerative diseases generally feature irreversible disease progression, limited symptomatic relief from existing therapies, and rigid long-term treatment demand, endowing these fields with lasting commercial value. As multiple pipelines continuously generate clinical data, the commercial upside of iRegene Therapeutics will keep expanding, forming a stable fundamental framework integrating a proprietary technology platform, diversified clinical pipelines and broad market potential.

The two financing rounds totaling RMB 470 million have been completed with diversified investors participating simultaneously, reflecting strong recognition of iRegene Therapeutics’ core value proposition from all types of capital institutions. This Series C+ round is led by Chengdu Sci-Tech Innovation Investment, with joint investment from China Capital Management, Wuxi Capital Group, Dingtai Star, Nanjing Xinjiye and HONY CAPITAL. Existing shareholders including Yuanxi Haihe Biomedical Industry Fund and Jinshajiang United Runpu Yuanfeng Venture Capital made follow-on investments. Financial capital, industrial capital and local sci-tech innovation platforms have joined forces to back the company.

Investors of various types share a unanimous view: off-the-shelf universal iPSC cell therapy represents a disruptive solution for degenerative diseases, and iRegene Therapeutics is one of the few platform enterprises in this sector that has accomplished clinical translation of multiple pipelines and laid an industrialization foundation.

As the lead investor of this round, local sci-tech innovation platform Chengdu Sci-Tech Innovation Investment values the company’s industrial synergy within the region, and recognizes its potential to link technology commercialization with the local cell therapy industrial ecosystem. Brokerage and financial investors including China Capital Management and HONY CAPITAL focus on the company’s increasingly clear capitalization roadmap and its capacity to deliver compelling stories to global capital markets.

The stance of industrial capital carries greater reference value for the whole industry. Industrial investors such as Dingtai Star and Nanjing Xinjiye participated in the financing mainly for the medium and long-term commercial value of iRegene Therapeutics’ pipelines. In addition, its cell therapy pipelines can form complementary synergies with traditional small-molecule and biologic drug businesses.

As a state-owned venture capital institution with deep cultivation in the cell therapy track, Wuxi Capital Group holds an optimistic view on the off-the-shelf production model of universal iPSC products. Compared with autologous cell therapies, the universal off-the-shelf iPSC model enables mass manufacturing, significantly cutting costs and improving drug accessibility, thereby fundamentally breaking the industry’s supply bottleneck. Wuxi Capital Group noted that iPSC technology can repair damaged nerve cells at the source, delivering disruptive value for untreatable degenerative chronic diseases. iRegene Therapeutics boasts an outstanding team with proven capabilities in clinical translation and implementation, which can continuously unlock the clinical value of its pipelines and consolidate the company’s position among the first-tier players in cell therapies for central nervous system disorders.

Continuous follow-on investments from existing shareholders serve as proof that the original investment thesis is steadily being realized. When Luminous Ventures and Apricot Capital led the previous Series C1 round, they pointed out that the company’s AI-enabled chemical induction technology directly addresses core industry pain points. Its team possesses world-class R&D and global execution capabilities, and the platform consistently delivers first-in-class pipelines worldwide. Platform scalability and efficient clinical translation constitute its core competitive strengths.

Continuous capital inflows across multiple financing rounds fully demonstrate the capital market’s recognition of iRegene Therapeutics’ technological moat, clinical reliability and long-term growth potential.

Following the completion of two consecutive financing rounds, iRegene Therapeutics has officially transitioned from the technology verification stage to a new phase featuring simultaneous clinical value realization and accelerated capitalization. This Series C+ round has introduced investors with diversified backgrounds, reshaping the company’s shareholder structure and strengthening the certainty of its capitalization roadmap.

Investors with diverse backgrounds each play their respective roles, forming a fully supportive system with complementary resources. Chengdu Sci-Tech Innovation Investment leverages its local industrial resources to help the company continuously upgrade its industrial manufacturing base and regional clinical translation ecosystem. Institutions including China Capital Management and HONY CAPITAL draw on their capital market resources to deliver all-round support for the company’s follow-up financing, outreach to global investors and listing roadmap planning. Industrial investors Dingtai Star and Nanjing Xinjiye bring opportunities for industrial collaboration, commercialization rollout and pipeline BD cooperation. Specialized healthcare funds such as Wuxi Capital Group and Jinshajiang United Runpu yuanfeng Venture Capital maintain deep engagement in the sector and provide steady funding for the company’s long-term R&D investment. The participation of multi-type capital breaks the limitations of single-category investment, delivering comprehensive resource backing for the company’s synchronized development across clinical development, industrialization and capital operation.

As the company advances into a new growth stage, its demands for global investor communications, cross-border financing and long-term capitalization planning have risen markedly. To strengthen its internal team, iRegene Therapeutics recently recruited seasoned international capital markets executive Tim Ruan, who will oversee all corporate capital operations. Tim previously served in the capital markets divisions of Goldman Sachs and Morgan Stanley, boasting extensive experience in cross-border investment banking, financing for innovative biotech firms, and liaising with institutional investors worldwide.

The recruitment of this international capital markets executive marks a pivotal upgrade to iRegene Therapeutics’ management system. Drawing on Tim Ruan’s hands-on experience in global capital markets, the company will refine its medium- and long-term financing plan, unify its value proposition for global investors, establish regular communication channels with overseas institutional investors, and systematically formulate its IPO roadmap. With this appointment, iRegene Therapeutics has built an integrated management framework covering global clinical development, large-scale industrial construction and international capital market operations, laying solid groundwork for subsequent clinical advancement of pipelines, BD collaborations and future listing on capital markets.

The successful closure of the two consecutive financing rounds constitutes a critical milestone for iRegene Therapeutics and reflects the evolving investment logic of the iPSC track. Capital investors have moved beyond simply chasing technological concepts, and instead favor leading enterprises with foundational platform technologies, multi-pipeline clinical advancement capabilities, global execution strength, and a clear capitalization path.

At present, iRegene Therapeutics has completed its transformation from a technology innovator to a clinical asset-driven platform biotech, officially entering a brand-new stage of clinical value realization and accelerated capitalization.

iRegene Therapeutics’ management stated that the company will accelerate global clinical development, overseas registration, industrial construction and capital preparation. Its core development focus will shift from platform iteration to clinical data delivery, pipeline value monetization and global industrial collaboration, aiming to bring China-originated proprietary iPSC cell therapy technologies to patients worldwide.